GDF2 and hepatocellular carcinoma: These data demonstrated that the BMP receptor inhibitor LDN-212854 inhibits HCC tumor growth and angiogenic signaling by suppressing BMP9-ID1 signaling, suggesting that targeting BMP9-ID1 signaling could be a promising therapeutic option for HCC patients.